These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14985805)

  • 1. Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting.
    Naicker KP; Li H; Heredia A; Song H; Wang LX
    Org Biomol Chem; 2004 Mar; 2(5):660-4. PubMed ID: 14985805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate-centered maleimide cluster as a new type of templates for multivalent peptide assembling. synthesis of multivalent HIV-1 gp41 peptides.
    Wang LX; Ni J; Singh S
    Bioorg Med Chem; 2003 Jan; 11(1):159-66. PubMed ID: 12467718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
    Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
    Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    Baldwin CE; Sanders RW; Deng Y; Jurriaans S; Lange JM; Lu M; Berkhout B
    J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
    Chong H; Xu S; Zhang C; Nie J; Wang Y
    J Clin Virol; 2009 Jul; 45(3):255-8. PubMed ID: 19487156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
    Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
    Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs.
    Shi W; Qi Z; Pan C; Xue N; Debnath AK; Qie J; Jiang S; Liu K
    Biochem Biophys Res Commun; 2008 Oct; 374(4):767-72. PubMed ID: 18682248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidine-Protected β-Thiol Asparagine: Applications in One-Pot Ligation-Desulfurization Chemistry.
    Sayers J; Thompson RE; Perry KJ; Malins LR; Payne RJ
    Org Lett; 2015 Oct; 17(19):4902-5. PubMed ID: 26398220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41.
    Gordon LM; Waring AJ; Curtain CC; Kirkpatrick A; Leung C; Faull K; Mobley PW
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):677-86. PubMed ID: 7576927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity.
    Cheng S; Chang X; Wang Y; Gao GF; Shao Y; Ma L; Li X
    J Med Chem; 2015 Feb; 58(3):1372-9. PubMed ID: 25594223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.
    Su SB; Gong WH; Gao JL; Shen WP; Grimm MC; Deng X; Murphy PM; Oppenheim JJ; Wang JM
    Blood; 1999 Jun; 93(11):3885-92. PubMed ID: 10339497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
    Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
    J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
    Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
    Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.